Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Watchlist Manager
Verrica Pharmaceuticals Inc Logo
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Watchlist
Price: 0.4891 USD 4.84% Market Closed
Market Cap: 44.9m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+93%
Revenue
Forecast
+170%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

VRCA Price Targets Summary
Verrica Pharmaceuticals Inc

Wall Street analysts forecast VRCA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRCA is 3.4 USD with a low forecast of 2.02 USD and a high forecast of 5.25 USD.

VRCA Lowest Forecast
Wall Street Target
2.02 USD
313% Upside
VRCA Average Forecast
Wall Street Target
3.4 USD
595% Upside
VRCA Highest Forecast
Wall Street Target
5.25 USD
973% Upside
Lowest
Price Target
2.02 USD
313% Upside
Average
Price Target
3.4 USD
595% Upside
Highest
Price Target
5.25 USD
973% Upside
Verrica Pharmaceuticals Inc Competitors:
Price Targets
LINCOLN
Lincoln Pharmaceuticals Ltd
73% Upside
VRNA
Verona Pharma PLC
25% Upside
DMP
Dermapharm Holding SE
24% Upside
600216
Zhejiang Medicine Co Ltd
36% Upside
LINCOLN
Lincoln Pharmaceuticals Ltd
73% Upside
VRNA
Verona Pharma PLC
25% Upside
DMP
Dermapharm Holding SE
24% Upside
600216
Zhejiang Medicine Co Ltd
36% Upside
600329
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
57% Upside
MVP
Medical Developments International Ltd
59% Upside
002001
Zhejiang Nhu Co Ltd
18% Upside
000538
Yunnan Baiyao Group Co Ltd
23% Upside

Revenue
Forecast

Revenue Estimate
Verrica Pharmaceuticals Inc

The compound annual growth rate of Verrica Pharmaceuticals Inc's revenue for the next 3 years is 94%.

N/A
Past Growth
94%
Estimated Growth
Estimates Accuracy
9%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Verrica Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Verrica Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-73%
Average Miss
What are analyst estimates?

See Also

Summary
VRCA intrinsic value, competitors valuation, and company profile.
DCF Valuation
VRCA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VRCA stock valuation using valuation multiples.
Wall Street Estimates
VRCA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VRCA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VRCA's stock price target?
Price Target
3.4 USD

According to Wall Street analysts, the average 1-year price target for VRCA is 3.4 USD with a low forecast of 2.02 USD and a high forecast of 5.25 USD.

What is Verrica Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
94%

The compound annual growth rate of Verrica Pharmaceuticals Inc's revenue for the next 3 years is 94%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 250,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.